2023-507493-41-00已完成3 期
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 293
- 试验地点
- 33
- 主要终点
- Annual relapse rate (ARR, based on confirmed relapses) measured over the 96 weeks
研究概览
简要总结
Demonstrate the effectiveness of ofatumumab 20 mg s.c. administered every 4 weeks in subjects with relapsing forms of MS who had breakthrough disease on fumarates or fingolimod.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of MS according to the 2017 Revised McDonald criteria
- •Relapsing MS: relapsing forms of MS (RMS) including RMS and secondary progressive MS (SPMS) (Lublin et al 2014)
- •Disability status at screening defined by Expanded Disability Status Scale (EDSS) score of 0 to 4 (inclusive)
- •MS treatment history with a maximum of 3 Disease Modifying Therapies (DMTs), where all fumarates are considered as one DMT
- •Subject transitioning from either any fumarate-based RMS approved therapies, such as dimethyl fumarate (DMF) or diroximel fumarate (DRF), or fingolimod which was administered for a period of at least 6 months, as their last DMT before first study drug administration
- •Breakthrough disease activity while the participant was adequately using fumarates or fingolimod prior to transitioning for a minimum of 6 months as evidenced by one or more clinically reported relapses or one or more signs of Magnetic Resonance Imaging (MRI) activity (e.g. Gd+ enhancement, new or enlarging T2 lesions)
- •Neurologically stable within one month prior to first study drug administration
排除标准
- •Subjects with primary progressive MS (Polman et al 2011) or SPMS without disease activity (Lublin et al 2014)
- •Subjects with active hepatitis B and C disease, assessed locally
- •Have received any live or live-attenuated vaccines within 4 weeks prior to first study drug administration
- •Have been treated with medications as specified or within timeframes specified (e.g. corticosteroids, ofatumumab, rituximab, ocrelizumab, alemtuzumab, natalizumab, daclizumab, cyclophosphamide, teriflunomide etc.)
- •Subjects suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the investigator
- •Subjects meeting criteria for neuromyelitis optica (Wingerchuk et al 2015)
- •Disease duration of more than 10 years since diagnosis
- •Pregnant or nursing (lactating) women
- •Women of child-bearing potential unless they are using highly effective forms of contraception during dosing and for at least 6 months after stopping study medication
- •Subjects with active chronic disease of the immune system other than MS or with immunodeficiency syndrome
- •Subjects with active systemic bacterial, fungal or viral infections (such as hepatitis, HIV, COVID-19), or known to have Acquired Immunodeficiency Syndrome (AIDS)
- •Subjects with neurological symptoms consistent with Progressive Multifocal Leukoencephalopathy (PML) or with confirmed PML
- •Subjects at risk of developing or having reactivation of syphilis or tuberculosis (e.g. subjects with known exposure to, or history of syphilis, or active or latent tuberculosis, even if previously treated), as confirmed by medical history or per local practice
结局指标
主要结局
Annual relapse rate (ARR, based on confirmed relapses) measured over the 96 weeks
Annual relapse rate (ARR, based on confirmed relapses) measured over the 96 weeks
次要结局
- Proportion of subjects with adverse events, including injection related reactions
- Proportion of patients with laboratory or vital signs results meeting abnormal criteria
- The proportion of subjects discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons
研究者
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
研究点 (33)
Loading locations...
相似试验
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumabMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMultiple sclerosisEUCTR2019-001341-40-NOovartis Pharma AG550
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approved therapies or fingolimod to ofatumumabMultiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001341-40-GRovartis Pharma AG555
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approved therapies or fingolimod to ofatumumabMultiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001341-40-CZovartis Pharma AG555
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approved therapies or fingolimod to ofatumumabMultiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001341-40-DEovartis Pharma AG555
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumabMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMultiple sclerosisEUCTR2019-001341-40-ITovartis Pharma AG550